RAPP
Rapport Therapeutics Inc

385
Mkt Cap
$1.33B
Volume
400,785.00
52W High
$42.27
52W Low
$6.43
PE Ratio
-10.37
RAPP Fundamentals
Price
$27.93
Prev Close
$27.97
Open
$27.85
50D MA
$28.34
Beta
1.43
Avg. Volume
369,198.25
EPS (Annual)
-$2.14
P/B
2.60
Rev/Employee
$0.00
$345.02
Loading...
Loading...
News
all
press releases
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine analysts that are currently covering the firm...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Rapport Therapeutics (NASDAQ:RAPP) Stock Rating Lowered by Wall Street Zen
Wall Street Zen lowered shares of Rapport Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·8d ago
News Placeholder
Rapport Therapeutics (NASDAQ:RAPP) Upgraded to Hold at Wall Street Zen
Wall Street Zen raised Rapport Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday...
MarketBeat·21d ago
News Placeholder
Abraham Ceesay Sells 5,833 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) CEO Abraham Ceesay sold 5,833 shares of Rapport Therapeutics stock in a transaction that occurred on Tuesday, January 20th. The stock was...
MarketBeat·23d ago
News Placeholder
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Short Interest Up 20.7% in December
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totaling 2,692,137...
MarketBeat·26d ago
News Placeholder
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Rating of "Moderate Buy" by Analysts
Shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight analysts that are presently covering the firm, Marketbeat...
MarketBeat·27d ago
News Placeholder
Rapport Therapeutics (NASDAQ:RAPP) Downgraded by Wall Street Zen to "Sell"
Wall Street Zen lowered Rapport Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·29d ago
News Placeholder
Rapport Therapeutics (NASDAQ:RAPP) Insider David Bredt Sells 8,500 Shares
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider David Bredt sold 8,500 shares of the stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an...
MarketBeat·29d ago
News Placeholder
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6.9% - Time to Sell?
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 6.9% - What's Next...
MarketBeat·1mo ago
News Placeholder
Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells 2,840 Shares of Stock
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider Krishnaswamy Yeleswaram sold 2,840 shares of Rapport Therapeutics stock in a transaction on Wednesday, December 31st. The shares...
MarketBeat·1mo ago
<
1
2
...
>

Latest RAPP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.